Skip to main content
OpenTrials
Completed

NCT Number: NCT01332357

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Disease Attributes Emergencies Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with asthma as determined by ICD-9 codes and asthma drug use
  • at least 12 years of age
  • discharged from an initial Emergency Department visit within 12 months

Exclusion criteria

  • Subjects with COPD or treatment for COPD

Treatment and study plan

Fluticasone propionate/salmeterol combination ED MD

Drug

Receipt of fluticasone propionate/salmeterol combination from the ED physician

Fluticasone propionate/salmeterol combination OP MD

Drug

Receipt of fluticasone propionate/salmeterol combination from the OP physician

Primary outcomes

  1. Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event

    Time frame: Data were collected during a 4-year period from January 1, 2004 to December 31, 2008.

    A subsequent asthma-related inpatient (IP) visit or emergency department (ED) visit were defined as visits within 6 months of the index event. The index event was defined as an asthma-related hospitalization or ED visit occuring between 2004 and 2008.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Apr 11, 2011
Registry last updated
Jul 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.